Reading between the lines of J&J's $1.75bn Alios buy

Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.

Johnson & Johnson highlighted the Phase II therapy AL-8178 for respiratory syncytial virus (RSV) on 30 September when it announced the $1.75bn acquisition of Alios BioPharma, but the most valuable aspect of the deal may be the privately-held company's preclinical hepatitis C virus (HCV) programs.

Nucleotide analogs – otherwise known as "nucs" – are hot properties in HCV given their role in all-oral, interferon-free regimens...

Welcome to Scrip

Create an account to read this article

More from Anti-infective

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from Therapy Areas

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.